TruSight Oncology UMI Reagents
Error correction with unique molecular identifiers (UMIs) for next-generation sequencing libraries.
Read More...
Total:
Product Highlights
These reagents reduce background noise in sequencing data, enabling detection of low-frequency variants, such as those found in cell-free DNA (cfDNA).
Reduced Error Rates
Circulating tumor DNA (ctDNA) may represent a very small fraction of cfDNA, near the limit of detection for next-generation sequencing (NGS). The TruSight Oncology UMI Reagents address this challenge with UMIs and error correction software, reducing error rates to < 0.007% and enabling detection of low-frequency variants. Lower error rates increase analytical specificity, resulting in higher confidence in NGS data.
Workflow Integration
The TruSight Oncology UMI Reagents include UMI adapters and indexes, plus DNA library prep and enrichment reagents. These reagents can also be paired with the TruSight Tumor 170 DNA oligos. Integration of UMIs does not create any extra steps in the library prep workflow.
Intuitive Software for Error Correction
The UMI Error Correction App aligns reads, then uses UMIs to exclude false positives, reducing variant calling errors. The UMI Error Correction App is available in the cloud-based BaseSpace Sequence Hub or for local installation.
Frequently Purchased Together
Specifications
Background Reduction Facilitates Accurate Variant Calling
To enable accurate detection of rare variants, UMIs are integrated with error correction software, enabling true mutations to be distinguished from background noise. The bottom panel illustrates how, by removing inherent errors that result in false positives, the reduced error rate allows true mutations (red dots) to be better distinguished from background noise (grey dots).
| Sequencing Run | Mean Error Rate (Uncollapsed Reads) | Mean Error Rate (Collapsed Reads) |
|---|---|---|
| 1 | 0.038% | 0.0023% |
| 2 | 0.043% | 0.0024% |
| 3 | 0.035% | 0.0024% |
| 4 | 0.084% | 0.0019% |
Library preparation was performed using the TruSight Oncology UMI Reagents paired with DNA content from the TruSight Tumor 170 DNA assay, and 31 samples were distributed among four independent sequencing runs on the HiSeq 4000 System. Mean error rates are shown with and without collapsed reads using the UMI Error Correction App.
